HeitmanJ.,Mandell, 2000.Bennett's principles and practice of infectious diseases,Mycopathologia 149 47 -8
HooperDC, 1993.Mechanisms of quinolone action and bacterial killing,Quinolone antimicrobial agents 53 -75
HooperDC, 1999.Mode of action of fluoroquinolones,Drugs 58 6 -10
OwensJr,RC , Ambrose,PG., 2000.Clinical use of the fluoroquinolones,Med Clin North Am 84 1447 -69
HooperDC, 2000.New uses for new and old quinolones and the challenge of resistance,Clin Infect Dis 30 243 -54
AmbrosePG,OwensJR,QuintilianiR,NightingaleCH, 1997.New generations of quinolones: with particular attention to levofloxacin,Conn Med 61 269 -72
DrewRH,GallisHA, 1988.Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application,Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 8 35 -46
SamanidouVF,DemetriouCE,PapadoyannisIN, 2003.Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC,Anal Bioanal Chem 375 623 -9
National, 2012.Library of Medicine's Medical Subject Headings online file (MeSH,, -
SamanidouVF,DemetriouCE,PapadoyannisIN, 2003.Direct determination of four fluoroquinolones, enoxacin, norfloxacin, ofloxacin, and ciprofloxacin, in pharmaceuticals and blood serum by HPLC,Anal Bioanal Chem 375 623 -9
MaliAD,BatheR,TamboliA, 2015.Simultaneous determination of Cefiximetrihydrate and Ofloxacin in pharmaceutical dosage form by second order derivative UV spectrophotometry,International Journal of Advances in Pharmaceutical Analysis 5 -
SmithJT,Supplement, 1986.The mode of action of 4-quinolones and possible mechanisms of resistance,J Antimicrob Chemother 18 21 -9
Macías-Cortés EdelC,Llanes-GonzálezL,Aguilar-FaisalL,AsbunBojalilJ, 2015.Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, doubleblind, placebocontrolled trial,PLoS One 10 e0118440 -
OngHX,TrainiD,BebawyM,YoungaPM, 2013.Ciprofloxacin Is Actively Transported across Bronchial Lung Epithelial Cells Using a Calu-3 Air Interface Cell Model,Antimicrob Agents Chemother 57 2535 -40
LandersdorferCB,KirkpatrickCM,KinzigM,BulittaJB,HolzgrabeU,JaehdeU,ReiterA,NaberKG,RodamerM, 2010.Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid,Br J Clin Pharmacol 69 167 -78
NaveedS,NaseemY,SamieS,KhanS,SiddiquiS., 2014.Bushra and Ramzan S. Degradation Study of Five Different Brands of Ciprofloxacin Using UVVisible Spectrophotometer and Their Comparitive study,Int Res J Pharm 5 189 -90
DavisR,MarkhamA,BalfourJA. Ciprofloxacin., 1996.An updated review of its pharmacology, therapeutic efficacy and tolerability,Drugs 51 1019 -74
EronLJ,HarveyLI,HixonDL,PoretzDM, 1985.Ciprofloxacin therapy of infections caused by Pseudomonas aeruginosa and other resistant bacteria,Antimicrob Agents Chemother 28 308 -10
BarkerAF,CouchL,FielSB,GotfriedMH,IlowiteJ,MeyerKC,O'donnellA,SahnSA,SmithLJ,StewartJO,AbuanT., 2000.Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis,Am J Respir Crit Care Med 162 481 -5
2009.Aerosol antibiotics in cystic fibrosis,Respiratory Care 54 658 -70
BourikasLA,KoliosG,ValatasV,NotasG,DrygiannakisI,PelagiadisI,ManousouP,KlironomosS,MouzasI,KouroumalisE., 2009.Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-b1 secretion and enhances the anti-proliferative effect of 5- fluorouracil,Br J Pharmacol 157 362 -70